Title : A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.

Pub. Date : 2017 May

PMID : 28065465






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The CGMT trial is a multicenter, phase II randomized, double-blinded, and placebo-controlled study, which is designed to evaluate the safety and efficacy of metformin in combination with gefitinib as first-line therapy in patients presenting with stage IIIb-IV non-small-cell lung cancer expressing the epidermal growth factor receptor mutant. Metformin epidermal growth factor receptor Homo sapiens